Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
P/E ratio for Evofem Biosciences, Inc. (EVFM)
P/E ratio as of 2023: 0.01
According to Evofem Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.01. At the end of 2022 the company had a P/E ratio of -0.05.
P/E ratio history for Evofem Biosciences, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 0.01 |
| 2022 | -0.05 |
| 2021 | -0.24 |
| 2020 | -1.27 |
| 2019 | -2.89 |
| 2018 | -0.73 |
| 2017 | -2.29 |
| 2016 | -1.19 |
| 2015 | -0.44 |
| 2014 | -9.45 |
| 2013 | -10.60 |
| 2012 | -20.33 |